NutriDex

The Supplement Research Compendium
🍯

Isomaltooligosaccharides (IMO)

Isomalto-oligosaccharides

A sweet, partly-digestible "fiber" whose prebiotic and fiber claims are weaker than the label suggests.

Preliminary evidence 🌾Prebiotics & Fibers🛡️Gut & Immune

✚ Updated · How we grade evidence

Evidence tier
Preliminary
Research weight
Citations
8 verified / 8
Classification
Prebiotics & Fibers
❝
What the evidence says. Early or small human trials; promising but not yet conclusive.

What is Isomaltooligosaccharides (IMO)?

Isomaltooligosaccharides (IMO) (Isomalto-oligosaccharides) is a prebiotic fiber used for modestly increased stool frequency, wet stool weight, and stool output in small trials of constipated elderly adults at ~10 g/day. NutriDex grades the human evidence as Preliminary. Isomaltooligosaccharides (IMO) are short glucose chains linked mainly by alpha-1,6 bonds, marketed as a low-calorie sweetener and prebiotic "fiber" widely used in protein bars and keto products. The honest picture is that much commercial IMO is substantially digested by human gut alpha-glucosidases into glucose, so it behaves more like a slowly digestible carbohydrate than a true resistant fiber and can raise blood glucose and insulin more than the label implies. Human evidence is thin: small, mostly older or Asian trials suggest a bifidogenic shift and modestly improved bowel function and stool frequency in constipated elderly adults at ~10 g/day, but there is no robust meta-analytic support and bifidogenic effects were not reproduced in European cohorts. Compared with inulin, GOS, or psyllium, IMO is a weakly-evidenced prebiotic, and its biggest practical caveat is that its true fiber content and glycemic impact often deviate from marketing.

Purported Benefits

✓Modestly increased stool frequency, wet stool weight, and stool output in small trials of constipated elderly adults at ~10 g/day
✓Shifted colonic microflora toward Bifidobacterium and Lactobacillus in small human studies (bifidogenic effect, but not reproduced in all populations)
✓Reduced total and LDL cholesterol in one small placebo-controlled diet-controlled trial of constipated elderly subjects
✓Can replace sugar as a partially-lower-calorie, lower-glycemic-index sweetener (GI ~35), though commercial IMO is still meaningfully digestible and raises glucose/insulin
✓Generally well tolerated at moderate doses with less gas than highly fermentable fibers, reflecting its lower fermentability

Evidence by outcome

The same supplement can be well-proven for one use and unproven for another — here is the human evidence graded outcome by outcome.

OutcomeEvidenceEffectStudies
Increased stool frequency / bowel function in constipated elderlySmall trials at ~10 g/day roughly doubled defecation, but a 2025 meta-analysis found modest, inconsistent effects. Preliminary ↑ benefit · moderate 2
Bifidogenic microbiome shiftSeen in small Asian studies but not reproduced in European adults; digestibility questions prebiotic status. Mixed ↔ mixed · small 2
Lowered total/LDL cholesterolOne small placebo-controlled, diet-controlled trial in constipated elderly; benefits faded after stopping. Preliminary ↑ benefit · small 1
Low-glycemic sweetener substitutionCommercial IMO is substantially digested to glucose, producing a glycemic response near dextrose, contrary to labeling. Mixed ↔ mixed · small 2

Dosing & Compounds

Typical Dose
Bowel/microbiome trials used about 10 g/day of active IMO, taken with food, for 4-8 weeks. As a sweetener it is used to taste in foods; product 'fiber' content is often overstated because much IMO is digested. Keep below ~30 g/day to limit GI symptoms.
Active Compounds
Bulk IMO powder and IMO syrup (e.g. VitaFiber, BioLigo) used in keto/low-sugar protein bars, cookies, and 'fiber' sweetenersListed on labels as isomalto-oligosaccharide, IMO, or VitaFiberProduced enzymatically from starch (corn, tapioca); also present in trace amounts in fermented foods like miso, soy sauce, sake, and honey

Safety & Cautions

Generally well tolerated; the main side effects are flatulence, bloating, borborygmi, soft stools, or osmotic diarrhea, which become more likely above roughly 30-40 g/day. As a FODMAP-type fermentable carbohydrate it can worsen gas and symptoms in people with IBS or fructose/oligosaccharide intolerance, who should be cautious. The most important caveat is metabolic, not toxic: commercial IMO is substantially digested to glucose, so people with diabetes or those tracking carbohydrates should not assume it is 'free' fiber; it can raise blood glucose and insulin, and actual fiber content frequently deviates from labels. Unlike bulk-forming fibers (psyllium, glucomannan) it poses no choking or esophageal-obstruction hazard. There is little safety data in pregnancy; standard food amounts are presumed safe, but supplemental doses should be discussed with a clinician. Educational only — always check with your doctor or pharmacist before combining Isomaltooligosaccharides (IMO) with any medicine.

Key Studies

Systematic review and meta-analysis of RCTs Non-digestible oligosaccharides & constipation meta-analysis 2025 ✓ Full text
Across randomized trials, non-digestible oligosaccharides (including IMO) had modest and inconsistent effects on stool frequency and consistency, underscoring limited high-quality evidence for IMO specifically.
Meta-analysis Liu 2025 (Nutrients) ✓ Full text
Systematic review and meta-analysis of 20 RCTs (n=1786) across seven non-digestible oligosaccharide types (including IMO) found supplementation significantly increased stool frequency, with larger effects in constipated individuals and short-term (≤3 wk) trials, and lowered fecal pH; certainty was low due to heterogeneity.
Randomized double-blind crossover trial Wu et al. 2018 ✓ Full text
In healthy adults, an IMO syrup dose-matched for 50 g carbohydrate produced a glycemic response similar to dextrose and GI tolerance similar to control, indicating commercial IMO is substantially digestible rather than a non-glycemic fiber.
RCT Gourineni 2018 (PMC5872719) ✓ Full text
Two randomized, double-blind, placebo-controlled crossover human studies in healthy adults showed a commercial IMO product was substantially digested and produced a measurable glycemic and insulin response with limited breath-hydrogen fermentation, questioning its labeled low-glycemic fiber status.
Placebo-controlled, diet-controlled trial Yen et al. 2011 ✓ PubMed
In 13 constipated elderly subjects, 10 g/day IMO for 4-8 weeks improved colonic Bifidobacterium profile and bowel function time-dependently and reduced total and LDL cholesterol, with benefits fading after discontinuation.
Controlled human trial Chen et al. 2001 ✓ PubMed
In constipated elderly men, ~10 g/day of IMO roughly doubled defecation frequency and increased wet stool output ~70% and dry stool weight ~55% versus a low-fiber control period.
Narrative/critical review Goffin et al. 2011 (review) ✓ Source
Reviews note bifidogenic effects of IMO were seen mainly in small Asian studies and were not reproduced in European adults, and question whether industrial IMO meets prebiotic criteria given its digestibility.
In vitro / mechanistic study Sorndech et al. 2022 ✓ PubMed
Mammalian alpha-glucosidases fully hydrolyzed IMOs to glucose (slowly), so IMOs are better classified as slowly digestible carbohydrates than as dietary fibers at physiological enzyme levels.
8 sources cited · 8 verified Search all studies on PubMed ↗

Common questions about Isomaltooligosaccharides (IMO)

What is Isomaltooligosaccharides (IMO) used for?

Isomaltooligosaccharides (IMO) is most often taken for Modestly increased stool frequency, wet stool weight, and stool output in small trials of constipated elderly adults at ~10 g/day, Shifted colonic microflora toward Bifidobacterium and Lactobacillus in small human studies (bifidogenic effect, but not reproduced in all populations), Reduced total and LDL cholesterol in one small placebo-controlled diet-controlled trial of constipated elderly subjects, Can replace sugar as a partially-lower-calorie, lower-glycemic-index sweetener (GI ~35), though commercial IMO is still meaningfully digestible and raises glucose/insulin. A sweet, partly-digestible "fiber" whose prebiotic and fiber claims are weaker than the label suggests.

Does Isomaltooligosaccharides (IMO) work — what does the evidence say?

Preliminary evidence. Early or small human trials; promising but not yet conclusive. Isomaltooligosaccharides (IMO) are short glucose chains linked mainly by alpha-1,6 bonds, marketed as a low-calorie sweetener and prebiotic "fiber" widely used in protein bars and keto products. The honest picture is that much commercial IMO is substantially digested by human gut alpha-glucosidases into glucose, so it behaves more like a slowly digestible carbohydrate than a true resistant fiber and can raise blood glucose and insulin more than the label implies. Human evidence is thin: small, mostly older or Asian trials suggest a bifidogenic shift and modestly improved bowel function and stool frequency in constipated elderly adults at ~10 g/day, but there is no robust meta-analytic support and bifidogenic effects were not reproduced in European cohorts. Compared with inulin, GOS, or psyllium, IMO is a weakly-evidenced prebiotic, and its biggest practical caveat is that its true fiber content and glycemic impact often deviate from marketing.

What is the typical dose of Isomaltooligosaccharides (IMO)?

Bowel/microbiome trials used about 10 g/day of active IMO, taken with food, for 4-8 weeks. As a sweetener it is used to taste in foods; product 'fiber' content is often overstated because much IMO is digested. Keep below ~30 g/day to limit GI symptoms.

Is Isomaltooligosaccharides (IMO) safe? Any cautions or side effects?

Generally well tolerated; the main side effects are flatulence, bloating, borborygmi, soft stools, or osmotic diarrhea, which become more likely above roughly 30-40 g/day. As a FODMAP-type fermentable carbohydrate it can worsen gas and symptoms in people with IBS or fructose/oligosaccharide intolerance, who should be cautious. The most important caveat is metabolic, not toxic: commercial IMO is substantially digested to glucose, so people with diabetes or those tracking carbohydrates should not assume it is 'free' fiber; it can raise blood glucose and insulin, and actual fiber content frequently deviates from labels. Unlike bulk-forming fibers (psyllium, glucomannan) it poses no choking or esophageal-obstruction hazard. There is little safety data in pregnancy; standard food amounts are presumed safe, but supplemental doses should be discussed with a clinician.

How many studies support Isomaltooligosaccharides (IMO)?

NutriDex cites 8 sources for Isomaltooligosaccharides (IMO), graded "Preliminary".

Cite this page
APA

Peh, D. (2026). Isomaltooligosaccharides (IMO) (Isomalto-oligosaccharides): Benefits, Dosage, Side Effects & Evidence. NutriDex — The Supplement Research Compendium. Retrieved 26 Jun 2026, from https://nutridex.info/s/imo

BibTeX
@misc{nutridex_imo,
  author       = {Peh, Daryl},
  title        = {Isomaltooligosaccharides (IMO) (Isomalto-oligosaccharides): Benefits, Dosage, Side Effects \& Evidence},
  year         = {2026},
  howpublished = {NutriDex --- The Supplement Research Compendium},
  url          = {https://nutridex.info/s/imo},
  note         = {Reviewed by Dr Daryl Peh, MBBS Singapore, MMed FM. Accessed 2026-06-26}
}

For medical claims, citing the underlying primary studies linked above is preferred. NutriDex is an educational reference, not medical advice.

← Back to the full dex · All substances